The goal of Fibriant™’s business strategy is to establish a profitable, sustainable R & D company that can substantially contribute to human healthcare at the short term and in the long run. To achieve this goal Fibriant will follow a step-by-step approach that will balance the generation of near-term revenues while preserving the potential for high returns over the longer term.
Fibriant™’s strategy to generate near-term revenues within the first three years is focussed on contract R & D services in the field of haemostasis and fibrinogen for other companies and supply of recombinant fibrinogen variants. Additional revenues will be generated by out-licensing IP, technology and know-how, outside the scope of Fibriant™’s own product development programs, to other parties.
Fibriant™’s long-term strategy to maximize revenues after three years involves contract manufacturing of clinical and commercial grade recombinant fibrinogen and out-licensing of product development opportunity after pre-clinical or early clinical Proof-of-Concept. The company may also spin-out specific assets into a “special purpose vehicle” for further development and funding.